Immuno-Oncology | Specialty

Targeted Therapy Advancements in Sarcoma Subtypes

March 25th 2020

Soft Tissue Sarcoma: Unmet Needs

March 25th 2020

The Prognostic Value of Molecular Testing

March 25th 2020

Switching Therapy: Secondary Mutations and Resistance

March 25th 2020

Current Treatment Landscape of Soft Tissue Sarcoma

March 25th 2020

Diagnostic Testing Procedure for Soft Tissue Sarcoma

March 25th 2020

Dr. Brody on In Situ Vaccinations for Hematologic Cancers

February 28th 2020

Joshua Brody, MD, discusses the development of in situ vaccinations, a vaccine that is created at the tumor site in patients with cancer.

Future Directions for Later-Line Therapy in R/R mCRC

February 25th 2020

Role of Immunotherapy in Microsatellite-Stable R/R mCRC

February 25th 2020

Relapsed/Refractory mCRC: Immunotherapy in MSI-High Tumors

February 25th 2020

Management of R/R mCRC: Sequencing for Later-Line Therapies

February 25th 2020

R/R Metastatic CRC: CORRECT, IMblaze370, and ReDOS Trials

February 25th 2020

Third-line and Later-line Therapies in R/R mCRC

February 25th 2020

Role of Rebiopsy and ctDNA Testing at Progression of mCRC

February 25th 2020

Molecular Status and Subsequent Therapies in mCRC

February 25th 2020

Initial Systemic Therapy for Metastatic Colorectal Cancer

February 25th 2020

Continuum of Care in Metastatic Colorectal Cancer

February 25th 2020

FDA Approval in HER2+ Breast Cancer, Priority Review in NSCLC, and More

February 1st 2020

Review Period Extended in GIST, Disappointing Findings in Lung Cancer, and More

February 1st 2020

Treating Unresectable HCC in the Community

February 1st 2020